Iodine-labeled tamoxifen uptake in primary human breast carcinoma.

Abstract

UNLABELLED:

Assessing tumor uptake and retention of (123)I-labeled tamoxifen (TX) could increase our understanding of TX's action and the mechanisms involved in resistance to the drug.

METHODS:

Nine untreated primary breast carcinoma patients underwent whole-body planar and tomographic (SPECT) imaging 30 min and 4-5 h after injection of 185 MBq (123)I-TX. Tumor-to-normal tissue uptake ratios (T/N) derived from SPECT images were related to estrogen receptor (ER) and progesterone receptor (PR) status.

RESULTS:

In 4 of 9 patients, all of whom were ER+/PR+, (123)I-TX tumor uptake was clearly depicted. In 2 of them, involved axillary lymph nodes were also visualized. T/N consistently increased over time. All ER+/PR- and ER-/PR- tumors as well as 2 ER+/PR+ tumors were (123)I-TX-.

CONCLUSION:

These preliminary findings suggest that (123)I-TX is preferentially taken up in alpha-ER+/PR+ breast tumors known to be more likely to respond to endocrine treatment.

• Authors: C Van de Wiele, V Cocquyt, R VandenBroecke, F De Vos, S Van Belle, K Dhaene, G Slegers, R A Dierckx
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 42 Issue 12 Pg. 1818-20 (Dec 2001) ISSN: 0161-5505 [Print] United States
• PMID: 11752079 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Iodine Radioisotopes
• Receptors, Estrogen
• Receptors, Progesterone
• Tamoxifen

Topics

• Breast Neoplasms (diagnostic imaging, metabolism)
• Carcinoma, Ductal, Breast (diagnostic imaging, metabolism)
• Carcinoma, Lobular (diagnostic imaging, metabolism)
• Feasibility Studies
• Female
• Humans
• Immunohistochemistry
• Iodine Radioisotopes
• Receptors, Estrogen (metabolism)
• Receptors, Progesterone (metabolism)
• Tamoxifen (pharmacokinetics, therapeutic use)
• Tomography, Emission-Computed, Single-Photon